<DOC>
	<DOCNO>NCT02598791</DOCNO>
	<brief_summary>With present study , investigator aim delineate effect GIP/GLP-1 receptor co-activity food intake , appetite , bone health fat metabolism overweight/obese subject .</brief_summary>
	<brief_title>GIP/GLP-1 Co-Activity Subjects With Obesity : Lowering Food Intake</brief_title>
	<detailed_description>The gut-derived incretin glucagon-like peptide-1 ( GLP-1 ) potent regulator gastric emptying , appetite food intake human whereas sister incretin hormone , glucose-dependent insulinotropic polypeptide ( GIP ) , seem independent effect variable human . Interestingly , recent data rodent show concomitant activation GIP GLP-1 receptor may potentiate satiety-promoting body weight-reducing effect GLP-1 . Also , evidence suggests GIP may important mediator bone remodelling lipid deposition . The effect simultaneous activation GIP GLP-1 receptor appetite , food intake , fat metabolism bone health thoroughly examine human . The aim study delineate effect GIP/GLP-1 receptor co-activation food intake , mechanism regulate food intake , fat bone metabolism obese subject . Material method : The investigator plan include 18 obese/overweight men without diabetes . The primary endpoint study food intake continuous intravenous infusion saline ( placebo ) , GIP , GLP-1 GIP+GLP-1 , respectively . Secondary endpoint include rest energy expenditure ( measure indirect calorimetry ) , appetite , satiety hunger assessment ( measure visual analogue scale ) , plasma insulin , C-peptide glucagon secretion , plasma triglyceride , cholesterol , free fatty acid response change plasma bone turnover marker .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Caucasian men Age 25 70 year Body mass index ( BMI ) 25 40 kg/m2 Diabetes prediabetes ( define glycated haemoglobin ( HbA1c ) â‰¥ 43 mmol/mol ) Anaemia ( define haemoglobin &lt; 8.3 mmol/l ) Any gastrointestinal disease may interfere endpoint variable Anorexia , bulimia binge eat disorder Allergy intolerance ingredient include standardised meal Tobacco smoke Any regular drug treatment discontinue minimum 18 hour Any physical psychological condition investigator feel would interfere trial participation</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>incretin hormone</keyword>
	<keyword>GIP</keyword>
	<keyword>GLP-1</keyword>
</DOC>